Loading
This study tests a PARP inhibitor; the registry reports that it is recruiting.
The registry lists NCT05123482 as recruiting, last updated 2026-09-11. Enrolment is 460 planned participants, an estimate. Interventions: AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib), AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), AZD8205 in combination with AZD9574, AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936). Primary measures include The number of patients with adverse events; The number of patients with serious adverse events. No results are posted in the registry; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Palacaparib, Saruparib, PARP, Endometrial cancer.
Shares Puxitatug samrotecan, Endometrial cancer, AstraZeneca, Antibody-drug conjugate (ADC).
Shares Palacaparib, PARP, AstraZeneca.
Shares Saruparib, PARP, AstraZeneca, Ovarian cancer.
Shares Saruparib, PARP, Ovarian cancer, Non-small-cell lung cancer.
Shares Saruparib, PARP, Small-cell lung cancer.
Shares Saruparib, PARP, Ovarian cancer.
Shares Rilvegostomig, AstraZeneca, Antibody-drug conjugate (ADC), Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/